New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
NCT00035269
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia.
- The patient must have S. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment.
- Patients cannot have taken more than one day of another antibiotic before entering
this study.
- Patients with HIV and a low CD4 count are excluded.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Los Angeles, California
- Jacksonville, Florida
- Naples, Florida
- Savannah, Georgia
- Springfield, Illinois
- Baton Rouge, Louisiana
- Baltimore, Maryland
- Ann Arbor, Michigan
- Royal Oak, Michigan
- Springfield, Missouri
- Hackensack, New Jersey
- Newark, New Jersey
- Somerville, New Jersey
- Staten Island, New York
- Stony Brook, New York
- Columbus, Ohio
- Zanesville, Ohio
- Fleetwood, Pennsylvania
- Hershey, Pennsylvania
- Ninety Six, South Carolina
- Spartanburg, South Carolina
- Harrogate, Tennessee
- Jackson, Tennessee
- Knoxville, Tennessee
- Memphis, Tennessee
- Memphis, Tennessee
- Memphis, Tennessee
- Nashville, Tennessee
- Dallas, Texas
- Houston, Texas
- Lubbock, Texas
- Charlottesville, Virginia
- Richmond, Virginia
- Seattle, Washington
- Bratislava,
- Mataro, Barcelona
- Mostoles, Madrid
- Barcelona,
- Barcelona,
- Barcelona,
- Girona,
- Madrid,
- Madrid,
- Madrid,
- Kaohsiung,
- Taoyuan,
Descriptive Information | |||
---|---|---|---|
Brief Title ICMJE | New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia) | ||
Official Title ICMJE | Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study | ||
Brief Summary | This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae) | ||
Detailed Description | Not Provided | ||
Study Type ICMJE | Interventional | ||
Study Phase ICMJE | Phase 3 | ||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||
Condition ICMJE |
| ||
Intervention ICMJE | Drug: Antibiotic | ||
Study Arms ICMJE | Not Provided | ||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||
Recruitment Information | |||
Recruitment Status ICMJE | Completed | ||
Actual Enrollment ICMJE | 230 | ||
Original Enrollment ICMJE | Not Provided | ||
Actual Study Completion Date ICMJE | May 2003 | ||
Primary Completion Date | Not Provided | ||
Eligibility Criteria ICMJE | Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria:
Exclusion Criteria:
| ||
Sex/Gender ICMJE |
| ||
Ages ICMJE | 13 Years and older (Child, Adult, Older Adult) | ||
Accepts Healthy Volunteers ICMJE | No | ||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries ICMJE | Slovakia, Spain, Taiwan, United States | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number ICMJE | NCT00035269 | ||
Other Study ID Numbers ICMJE | M12600071 A5951056 | ||
Has Data Monitoring Committee | Not Provided | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement ICMJE | Not Provided | ||
Responsible Party | Not Provided | ||
Study Sponsor ICMJE | Pfizer | ||
Collaborators ICMJE | Not Provided | ||
Investigators ICMJE | Not Provided | ||
PRS Account | Pfizer | ||
Verification Date | April 2011 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |